ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback